3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Not yet recruiting
2
Sponsor Class
OTHER
6
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Melanoma
2
Carcinoma, Hepatocellular
2
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Squamous Intraepithelial Lesions
1
Prostatic Neoplasms
1
Liver Diseases
1
Interventions
Sorafenib
79
pembrolizumab
37
Bevacizumab
36
Nivolumab
33
lenvatinib
30
atezolizumab
24
durvalumab
17
Oxaliplatin
12
Ipilimumab
12
regorafenib
9
Capecitabine
9
tremelimumab
8
Injections
8
Doxorubicin
8
tislelizumab
7
sintilimab
7
Fluorouracil
7
cabozantinib
6
budigalimab
6
brivanib
6
Ramucirumab
6
toripalimab
5
Gemcitabine
5
Everolimus
5
Cyclophosphamide
5
ADI PEG20
5
fludarabine
4
Sunitinib
4
Leucovorin
4
E-7386
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Hepatocellular
×
Electroporation
×
Clear all
NCT07191548
2025-10-10
LIVERMET-IRE
Angiodynamics, Inc.
Phase NA
Not yet recruiting
50 enrolled
NCT07192731
2025-10-10
LIVERHCC-IRE
Angiodynamics, Inc.
Phase NA
Not yet recruiting
50 enrolled